RBC Capital: 'Miebo remains the second-largest Rx DED drug in the US with 22.8% market share'

June 5, 2026 8:49 AM

RBC Capital analyst Douglas Miehm reiterated an Outperform rating and $21.00 price target on Bausch & Lomb Corp. (NYSE: BLCO).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found